DOI: https://doi.org/10.22141/2224-0713.1.95.2018.127413

Pain, anxiety, sleep disturbances — three targets for pregabalin with neuropathic back pain

V. Nikolaienko

Abstract


The article deals with the advantages of pregabalin (Sudorega®) as a first-line drug for patients with chronic neuropathic back pain. Analgesic effect of the drug in combination with the ability to correct sleep disturbances and psychoemotional state allows achieving therapeutic success even in severe forms of the disease resistant to traditional therapy. Among other advantages of Sudorega® — a high safety profile, the absence of drug-drug interactions, which allow it to be used in patients with polymorbidity, in the elderly; price affordability.

Keywords


neuropathic pain; dorsalgia; chronic low-back pain; sleep disturbances; psychoemotional state; anxiety; pregabalin

References


Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015 / GBD 2015 Disease and Injury Incidence and Prevalence Collaborators // Lancet. 2016 Oct 8; 388(10053): 1545-1602. doi: 10.1016/S0140-6736(16)31678-6.

Taguchi T., Igarashi A., Watt S. et al. Effectiveness of pregabalin for the treatment of chronic low back pain with accompanying lower limb pain (neuropathic component): a non-interventional study in Japan // J. Pain Res. 2015 Aug 5; 8: 487-497. doi: 10.2147/JPR.S88642.

Finan P.H., Goodin B.R., Smith M.T. The association of sleep and pain: An update and a path forward // Pain. 2013; 14(12): 1539-1552. https://doi.org/10.1016/j.jpain.2013.08.007

Кукушкин М.Л., Полуэктов М.Г. Современные представления о хронической боли и ее отношении к состоянию сна // Журнал неврологии и психиатрии им. С.С. Корсакова. — 2017. — Вып. 2. — С. 19-27; doi.org/10.17116/jnevro20171174219-27

Toelle T.R., Varvara R., Nimour M., Emir B., Brasser M. Pregabalin in Neuropathic Pain Related to DPN, Cancer and Back Pain: Analysis of a 6-Week Observational Study // The Open Pain Journal. 2012; 5: 1-11. doi: 10.2174/1876386301205010001

Якупов Э.З., Якупова С.П., Муслимова Е.А Мультивекторный характер купирования острой и хронической боли и необходимость использования копинг-стратегий ее преодоления // Журнал неврологии и психиатрии. — 2015. — № 12. — С. 98-104 doi: 10.17116/jnevro201511511298-103

Данилов А.Б., Данилов Ал.Б. Биопсихосоциокультурная модель и хроническая боль // Современная терапия в психиатрии и неврологии. — 2013. — № 1. — С. 30-36.

http://mtd.dec.gov.ua/images/dodatki/311_2012/dod_311_

ykpmd.pdf

Finnerup N.B., Attal N., Haroutounian S. et al. Pharmacothe­rapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations // The Lancet Neurology. 2015; 14(2): Р. 162-173. doi:10.1016/S1474-4422(14)70251-0.

Attal N., Cruccu G., Baron R. et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision // Eur. J. of Neurology. 2010; Vol. 17: P. 1113-1123.

Alles S.R.A., Smith P.A. Etiology and Pharmacology of Neuropathic Pain. Pharmacol Rev. 2018 Apr; 70(2): 315-347. doi: 10.1124/pr.117.014399.

Verma V., Singh N., Singh Jaggi A. Pregabalin in Neuropathic Pain: Evidences and Possible Mechanisms // Current Neuropharmacology. 2014; 12(1): Р. 44-56. doi:10.2174/1570159X1201140117162802

Fudin J. How Gabapentin Differs From Pregabalin // Рharmacy Times, 2015. Sept. 22, http://www.pharmacytimes.com/contributor/jeffrey-fudin/2015/09/how-gabapentin-differs-from-pregabalin

Bockbrader H.N., Wesche D., Miller R.A., Chapel S., Janiczek N., Burge P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin // Clin. Pharmacokinet. 2010; 49(10): P.661-669.

Schug S.A., Parsons B., Almas M., Whalen E. Effect of Concomitant Pain Medications on Response to Pregabalin in Patients with Postherpetic Neuralgia or Spinal Cord Injury-Related Neuropathic Pain // Pain Physician. 2017 Jan-Feb; 20(1): E53-E63.

Snedecor S.J., Sudharshan L., Cappelleri J.C., Sadosky A., Desai P., Jalundhwala Y, Botteman M. Systematic review and meta-analysis of pharmacological therapies for pain associated with postherpetic neuralgia and less common neuropathic conditions // Int. J. Clin. Pract. 2014 Jul; 68(7); Р. 900-918. doi: 10.1111/ijcp.12411.

Onouchi K., Koga H., Yokoyama K., Yoshiyama T. An open-label, long-term study examining the safety and tolerability of pregabalin in Japanese patients with central neuropathic pain // J. Pain Res. 2014; 7: 439-447.

Ogawa S., Arakawa A., Hayakawa K., Yoshiyama T. Pregabalin for Neuropathic Pain: Why Benefits Could Be Expected for Multiple Pain Conditions. // Clin. Drug. Investig. 2016 Nov; 36(11): Р. 877-888.

TGA Австралии: регистрация ARTG № 263081, 263055, 263074; Режим доступа, 09 2017: http://tga-search.clients.funnelback.com/s/search.html?collection=tga-artg&profile=record&meta_i=263081. http://tga-search.clients.funnelback.com/s/search.html?collection=tga-artg&profile=record&meta_i=263055. http:// tga-search.clients.funnelback.com/s/search.html?collection=tga-artg&profile28.

Дослідження «Фармстандарт» компанії «Моріон»: дослідження ринку лікарських засобів України в сегменті АТХ.

http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con763744.pdf




Copyright (c) 2018 INTERNATIONAL NEUROLOGICAL JOURNAL

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта